Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Exclusivity Extended into December 2042 Kansas City, Kan. — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and…